BiotechTube
Home/Pipeline/TROCEPT-02 (ATTR-02)

TROCEPT-02 (ATTR-02)

Not Specified

PreclinicalActive

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active
Company
Accession Therapeutics

About Accession Therapeutics

Accession Therapeutics is an emerging private biotech company pioneering a differentiated approach in immuno-oncology with its Trocept platform, a stealth virus technology engineered for tumor-specific entry. The company has advanced its lead candidate, TROCEPT-01 (ATTR-01), into a Phase 1 trial (ATTEST) for solid cancers and is building a broader pipeline. Backed by significant recent funding and led by an experienced team, including immuno-oncology pioneer Bent Jakobsen, Accession is positioning itself to address the limitations of current immunotherapies.

View full company profile

Therapeutic Areas

Oncology

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved